116834-96-9

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine,3-methyl-(9CI)
• Synonyms: 1H-Pyrazolo[3,4-b]pyridine,3-methyl-(9CI);3-methyl-1H-pyrazolo[3,4-b]pyridine;3-Methyl-1H-pyrazolo[3,4-b]pyridine ,97%;3-methyl-1H-pyrazolo[3,4-b]pyridine (en);1H-Pyrazolo[3,4-b]pyridine,3-Methyl-
• CAS NO: 116834-96-9
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15
• Product Categories: PYRIDINE;Heterocycle-Pyridine series
• Mol File: 116834-96-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 158-160°
• Boiling Point: 304.3 °C at 760 mmHg
• Flash Point: 146.9 °C
• Appearance: /
• Density: 1.273 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.52±0.20(Predicted)
• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine,3-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine,3-methyl-(9CI)(116834-96-9)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine,3-methyl-(9CI)(116834-96-9)

Safety Data

• Statements: 20/21/22
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 116834-96-9(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C7H7N3/c1-5-6-3-2-4-8-7(6)10-9-5/h2-4H,1H3,(H,8,9,10)

Upstream product

• 372-48-5 2-fluoropyridine 
• 488149-34-4 2-chloro-N-methoxy-N-methyl-pyridine-3-carboxamide 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 2942-59-8 2-chloronicotinic acid 
• 131674-39-0 2-chloro-3-(1-hydroxyethyl)pyridine 
• 109-09-1 2-chloropyridine 
• 79574-70-2 1-(2-fluoropyridin-3-yl)ethan-1-one 
• 31230-17-8 3-methyl-5-aminopyrazole 
• 14188-94-4 3-acetylpyridine N-oxide 
• 350-03-8 methyl-3-pyridylketone 
• 102-52-3 malonaldehydebis(dimethylacetal) 
• 55676-21-6 3-acetyl-2-chloropyridine 

Downstream Products

• 62908-83-2 3-methyl-5-nitropyrazolo<3,4-b>pyridine 
• 116855-08-4 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 174180-77-9 tert-butyl 3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 877770-64-4 1-(2,4-dichlorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 916325-83-2 pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 1027990-21-1 3-(bromomethyl)-1H-pyrazolo[3,4-b]pyridine 
• 1034474-19-5 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile 
• 1034474-21-9 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-1,2,3-benzotriazol-4-yl]oxy}benzonitrile 
• 1034474-33-3 3-chloro-5-{[5-chloro-1-(1-t-butyloxycarbonyl-1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile 
• 1034474-40-2 tert-butyl 3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 1034474-46-8 tert-butyl {2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]ethyl}carbamate 
• 1034474-45-7 tert-butyl {2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]ethyl}methylcarbamate 
• 1034474-24-2 2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]ethanaminium chloride 
• 1034474-22-0 2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]-N-methylethanaminium chloride 

Relevant articles and documents

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.